Considering the therapeutic potential of PPARγ agonists, which are FDA-approved for Type 2 Diabetes Mellitus, it becomes evident that these agents hold promise for preeclampsia treatment, particularly in patients with risk factors such as hyperglycemia. This evidence concerns the gene PPARG and diabetes mellitus.